inhibitor

(redirected from metalloproteinase inhibitor)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia.
Related to metalloproteinase inhibitor: metalloprotease inhibitor
See: deterrent
References in periodicals archive ?
Metalloproteinase inhibitors and the prevention of tissue breakdown.
Metalloproteinase inhibitor attenuates neointima formation and constrictive remodeling after angioplasty in rats: augmentative effect of alpha (v) beta (3) receptor blockade.
Its lead product, marimastat, a matrix metalloproteinase inhibitor, is in Phase III development for the treatment of cancer and has been licensed worldwide to Schering-Plough Corporation except for Japan and the Far East where it has been licensed to Tanabe Seiyaku Co.
The company has licensed its matrix metalloproteinase inhibitor programme to US drugs giant Bristol- Myers Squib and announced a major deal with Zeneca this year.
Marimastat is a matrix metalloproteinase inhibitor and a potential anti-cancer treatment that has been licensed to Schering-Plough Corporation.
Study 140, a clinical trial of the oral matrix metalloproteinase inhibitor, marimastat, in patients with small cell lung cancer, has been completed and the data have been collected.
Matrix Metalloproteinase Inhibitor Prevents Acute Lung Injury After Cardiopulmonary Bypass, Circulation, 1999;100:400-406.
Marimastat, a matrix metalloproteinase inhibitor, is in Phase III development for the treatment of cancer, BB-3644, a follow-on to marimastat, is in Phase I development for cancer, BB-10153 has completed Phase I development for cardiovascular disease; and BB-2827, a collagenase inhibitor for inflammation, is in Phase I development.
British Biotech (NASDAQ:BBIOY) announces the results of Study 186, a clinical trial of the oral matrix metalloproteinase inhibitor, marimastat.
British Biotech announces the results of Study 131, a Phase III clinical trial of the oral matrix metalloproteinase inhibitor, marimastat.
Its lead product, marimastat, a matrix metalloproteinase inhibitor, is in Phase III development for the treatment of cancer and has been licensed worldwide to Schering Plough Corporation except for Japan and the Far East where it has been licensed to Tanabe Seiyaku Co.
Matrix metalloproteinase inhibitors in rheumatic diseases.

Full browser ?